The Cardiovascular business, a key segment, is experiencing significant growth driven by the successful commercialization of its AGENT™ Drug-Coated Balloon and Farapulse™ Pulsed Field Ablation (PFA) System.
Filing excerpt
In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our coronary therapies franchise, led by our AGENT™ Drug-Coated Balloon, and our Electrophysiology business unit, led by our Farapulse™ Pulsed Field Ablation (PFA) System.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
sec-10qproductLaunchGet every 10-Q signal for Boston Scientific and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Boston Scientific this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/62e88d2e-3ee3-4dd8-94e8-c799ac8d6100 returns this record as JSON. POST /v1/companies/enrich returns every signal for bostonscientific.com.
{
"signal_id": "62e88d2e-3ee3-4dd8-94e8-c799ac8d6100",
"signal_type": "sec-10q",
"signal_subtype": "productLaunch",
"detected_at": "2026-08-04T07:04:22.117+00:00",
"company": {
"name": "Boston Scientific",
"domain": "bostonscientific.com"
},
"data": {
"detail": "The Cardiovascular business, a key segment, is experiencing significant growth driven by the successful commercialization of its AGENT™ Drug-Coated Balloon and Farapulse™ Pulsed Field Ablation (PFA) System. This focus on new product rollouts indicates budget allocation for sales enablement, marketing campaigns, and supply chain logistics to support the launch.",
"metrics": {
"timeframe": "current_quarter"
},
"summary": "New products AGENT™ and Farapulse™ drive strong growth in Cardiovascular unit.",
"excerpts": "In the second quarter and first six months of 2026, reported net sales growth was primarily driven by our coronary therapies franchise, led by our AGENT™ Drug-Coated Balloon, and our Electrophysiology business unit, led by our Farapulse™ Pulsed Field Ablation (PFA) System.",
"relevance": 0.8,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/885725/000088572526000053/bsx-20260630.htm",
"filing_date": "2026-08-03",
"filing_year": 2026,
"fiscal_year": 0,
"fiscal_year_end": "06/30",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"technologies_mentioned": [
"Drug-Coated Balloon",
"Pulsed Field Ablation (PFA)"
]
}
}
curl https://signals.autobound.ai/v1/signals/62e88d2e-3ee3-4dd8-94e8-c799ac8d6100 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bostonscientific.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.